ReviewCurrent rheumatology reports2018
Tregs in SLE: an Update.
Review in Current rheumatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Recent advances in the positive role ofFrontiers in immunology · 2026Review
- Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics.Signal transduction and targeted therapy · 2025Review
- Pharmacological mechanisms of traditional Chinese medicine metabolites in regulating Treg cells: an integrative pathway review.Frontiers in pharmacology · 2025Review
- Systemic lupus erythematosus: pathogenesis and targeted therapy.Molecular biomedicine · 2024Review
- [Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy.Biomedicines · 2023Review
- Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Review
- Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.Frontiers in immunology · 2023Review
- A decreased number of circulating regulatory T cells is associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus.Immunity, inflammation and disease · 2022Article
- Impact of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Rheumatic Disease Patients on T Helper Cell Differentiation.International journal of molecular sciences · 2022Article
- Gut Microbiota in Systemic Lupus Erythematosus and Correlation With Diet and Clinical Manifestations.Frontiers in medicine · 2022Article
- Autoimmunity and Cancer-Two Sides of the Same Coin.Frontiers in immunology · 2022Review
- T Cells in Systemic Lupus Erythematosus.Rheumatic diseases clinics of North America · 2021Review
- Splicing factor SRSF1 is indispensable for regulatory T cell homeostasis and function.Cell reports · 2021Article
- The Role of Sirtuin-1 in Immune Response and Systemic Lupus Erythematosus.Frontiers in immunology · 2021Review
- Rapid expansion of Treg cells protects from collateral colitis following a viral trigger.Nature communications · 2020Article
- T Cell Metabolism: A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus.Frontiers in immunology · 2020Review
- Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 TrpFrontiers in immunology · 2019Article
- Immunomodulatory Effects of Molecular Hydrogen Therapy in Systemic Lupus Erythematosus With Pericarditis and Pleuritis: A Case Report.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThere has been great interest in understanding why T regulatory cells (Tregs) are reduced in number and/or in function in several autoimmune diseases including systemic lupus erythematosus (SLE). Although research has provided some answers, there is still much to learn. RECENT
findingsRecent investigations on the mechanisms responsible for the impairment of the Tregs in SLE have identified relevant abnormalities in cellular and molecular pathways that have been instrumental in the design of studies in animal models and in the development of pilot immunotherapeutic studies in lupus patients. We review the progress made in the field in the last 5 years, discussing the mechanistic studies, together with the preclinical and clinical works that are moving forward the understanding of the physiopathology of Tregs in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.